Cyanotech (CYAN) Q4 2024 earnings summary

Executive summary

• Fiscal year net sales were $23.1 million, down 0.5% year-over-year, with a shift toward packaged sales and declines in bulk spirulina due to price sensitivity and international competition.

• Gross profit margin declined to 25.8% from 31.3% year-over-year, with gross profit at $5.9 million.

• Operating loss widened to $4.6 million from $2.9 million; net loss increased to $5.3 million ($0.81/share) from $3.4 million ($0.55/share).

• Fourth quarter net sales rose 10.7% year-over-year to $6 million, but gross margin fell to 11.3% and net loss increased to $2.1 million ($0.30/share).

• Debt increased slightly by $209,000 over the year, with management focused on cost control and inventory.

Financial highlights

• Fiscal 2024 net sales: $23.1 million vs. $23.2 million in 2023; gross profit: $5.9 million vs. $7.3 million; operating loss: $4.6 million vs. $2.9 million.

• Net loss: $5.3 million ($0.81/share) vs. $3.4 million ($0.55/share) in 2023.

• Q4 2024 net sales: $6 million (+10.7% YoY); gross profit: $675,000 (margin 11.3%); net loss: $2.1 million ($0.30/share).

• Year-end cash was $707,000 and working capital $2 million, down from $974,000 and $5.4 million, respectively, at prior year-end.

• Total assets: $25.1 million; total liabilities: $13.3 million; stockholders' equity: $11.8 million at March 31, 2024.

Outlook and guidance

• Management expects increased demand and has secured preliminary financing to support supply expansion.

• Strategic initiatives include sales team restructuring, new product launches in gummy formats, and enhanced market messaging focused on transparency and sustainability.